Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 3061-3066

  D'Avolio, Antonio ^a   Carcieri, Chiara ^b   Cusato, Jessica ^a   Simiele, Marco ^a   Calcagno, Andrea ^a   Allegra, Sarah ^a   Sciandra, Mauro ^a   Trentini, Laura ^a   Di Perri, Giovanni ^a   Bonora, Stefano ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

HIV antiviral therapy; Intracellular concentrations; Pharmacogenetics; Pharmacokinetics; Protease inhibitors; Therapeutic drug monitoring

Indexed keywords

ATAZANAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; RITONAVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; ABCB1 PROTEIN, HUMAN; BIOLOGICAL MARKER; MULTIDRUG RESISTANCE PROTEIN; OLIGOPEPTIDE; ORGANIC ANION TRANSPORTER; PYRIDINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; STEROID RECEPTOR;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CELL COUNT; CLINICAL ARTICLE; COULTER COUNTER; DESCRIPTIVE RESEARCH; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG PENETRATION; FEMALE; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETICS; INTRACELLULAR FLUID; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTRACELLULAR FLUID; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; RECEPTORS, STEROID; RITONAVIR;

EID: 84923065347     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku234     Document Type: Article

References (45)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. van Heeswijk RP, Veldkamp A, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6:201-29.
3. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002; 36:702-6.
4. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001; 11:87-98; quiz 107-8.
5. Jayakanthan M, Chandrasekar S, Muthukumaran J et al. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for highly active antiretroviral therapy in HIV/AIDS. J Mol Graph Model 2010; 28:455-63.
6. Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 2010; 107:18422-7.
7. Canta F, Marrone R, Bonora S et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother 2005; 55:280-1.
8. Tsiodras S, Mantzoros C, Hammer S et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160:2050-6.
9. Bonora S, Lanzafame M, D'Avolio A et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008; 46:146-7.
10. Gonzalez de Requena D, Calcagno A, Bonora S et al. Unexpected drugdrug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006; 20:1977-9.
11. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54:982-90.
12. Bazzoli C, Jullien V, Le Tiec C et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010; 49:17-45.
13. Khoo SH, Hoggard PG, Williams I et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother 2002; 46:3228-35.
14. Crommentuyn KM, Mulder JW, Mairuhu AT et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther 2004; 9:779-85.
15. Breilh D, Pellegrin I, Rouzes A et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18:1305-10.
16. Ford J, Boffito M, Maitland D et al. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mgadministered once daily in HIV-infected patients. JAntimicrob Chemother 2006; 58:1009-16.
17. Fletcher CV, Kawle SP, Kakuda TN et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIVinfected persons. AIDS 2000; 14:2137-44.
18. Simiele M, D'Avolio A, Baietto L et al. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter counter to determine intracellular drug concentrations. Antimicrob Agents Chemother 2011; 55:2976-8.
19. D'Avolio A, Simiele M, Siccardi M et al. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. J Pharm Biomed Anal 2011; 54:779-88.
20. D'Avolio A, Simiele M, Calcagno A et al. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. J Antimicrob Chemother 2013; 68:907-10.
21. Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther 2004; 9:97-101.
22. Summary of Product Characteristics-Reyataz. http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000494/WC500056380.pdf (17 February 2014, date last accessed).
23. D'Avolio A, Baietto L, Siccardi M et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30:662-9.
24. Janneh O, Owen A, Chandler B et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19:2097-102.
25. Janneh O, Jones E, Chandler B et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60:987-93.
26. Pasanen MK, Neuvonen M, Neuvonen PJ et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006; 16:873-9.
27. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 9:19-33.
28. Tirona RG, Leake BF, Merino G et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001; 276:35669-75.
29. Kohlrausch FB, de Cassia Estrela R, Barroso PF et al. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 2010; 69:95-8.
30. Lubomirov R, di Iulio J, Fayet A et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-30.
31. Calcagno A, Nozza S, Gonzalez de Requena D et al. Pharmacokinetics of maraviroc administered at 150 mgonce daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. J Antimicrob Chemother 2013; 68:1686-8.
32. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794:860-71.
33. Iwai M, Suzuki H, Ieiri I et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004; 14:749-57.
34. van der Deure WM, Friesema EC, de Jong FJ et al. Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. Endocrinology 2008; 149:4695-701.
35. Janneh O, Hartkoorn RC, Jones E et al. Cultured CD4 T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 2008; 155:875-83.
36. Lee CG, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-601.
37. Lucia MB, Golotta C, Rutella S et al. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr 2005; 39:635-7.
38. Tirona RG, Lee W, Leake BF et al. The orphan nuclear receptor HNF4a determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9:220-4.
39. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26:180-5.
40. Michaud V, Bar-Magen T, Turgeon J et al. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 2012; 64:803-33.
41. Tang K, Ngoi SM, Gwee PC et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12:437-50.
42. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-94.
43. Siccardi M, D'Avolio A, Baietto L et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C_T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47:1222-5.
44. Schipani A, Siccardi M, D'Avolio A et al. Population pharmacokinetic modeling of the association between 63396C_T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 2010; 54:5242-50.
45. Tempestilli M, Elisei F, Cimini E et al. Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein. J Antimicrob Chemother 2014; 69:1760-6.